Our new design is here! Clearer, more modern, more international. With our new design and visual language we have achieved a strong visual alignment with the corporate identity of Revvity, Inc. At the same time, we harmonized the visual appearance of the Euroimmun and IDS brands creating a new modernized look which visually reflects our shared identity and growing collaboration. But what really counts remains the same: our […]
Euroimmun is modernizing its brand appearance Our company has undergone significant developments in recent years. This will now also be reflected in our visual appearance. At the ADLM in Chicago (July 27–31, 2025), we will show you our new, modernized look for the first time, underlining our innovative power and our international orientation. But, of
On 15th April 2025, the European Commission authorised lecanemab (monoclonal anti-amyloid (beta) antibody; trade name: Leqembi from Eisai and Biogen) in the European Union to treat early Alzheimer’s disease. A decision was long awaited after the positive opinion on the marketing authorisation of the medicine by the European Medicines Agency (EMA) in November 2024. The
Press release, March 3rd 2025 Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s
At the end of last year, EUROIMMUN and Xpedite Diagnostics announced the start of a strategic partnership. Now the time has come: EUROArray SwiftX-traction is a rapid extraction procedure enabling the isolation of pathogen DNA for further analysis using EUROIMMUN’s EUROArrays. It has been especially developed for EUROIMMUN and is now approved worldwide for diagnostic
